Physician profile
Beth A Cook
NPI 1396791471
$5,740.42
in general payments reported to CMS, 2019-2025
45 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $382 · 2021: $739 · 2022: $1,097 · 2023: $821 · 2024: $784 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,709 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,708.57 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,163.48 | 2019-2025 | Orilissa, Lo Loestrin Fe, Liletta |
| Mayne Pharma Commercial LLC | $428.45 | 2021-2025 | |
| Hologic Sales and Service, LLC | $333.01 | 2019-2025 | Acessa Provu System, Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $324.46 | 2022-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $314.36 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $287.84 | 2024-2025 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $254.45 | 2020-2024 | Slynd |
| Channel Medsystems, INC. | $243.69 | 2022-2025 | |
| Sage Therapeutics, LLC | $208.42 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $205.84 | 2019-2025 | |
| Shield Therapeutics INC | $189.96 | 2022-2025 | Accrufer |
| Optumhealth Care Solutions, LLC | $146.01 | 2023-2024 | Vivify Health Care Team Portal 001, Eitan Medical, Vivify Health Care Team Portal |
| Organon LLC | $126.77 | 2021-2025 | Nexplanon |
| Aspira Women'S Health INC | $126.55 | 2022-2024 | Ova1 |
| Daiichi Sankyo INC. | $100.92 | 2022-2024 | Injectafer |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.